Marijuana users found to have 16% lower fasting insulin levels than non-users
Marijuana use has been associated with lower fasting insulin levels
<p> </p> <div> People who smoke marijuana have been found to have 16 per cent lower fasting insulin levels than non-users, according to research published in The American Journal of Medicine.</div> <div> </div> <div> In light of the findings, professor of medicine at the University of Arizona College of Medicine, Tucson, Joseph Albert, called for more basic and clinical research into the short and long-term effects of marijuana in a variety of clinical settings, including cancer and diabetes. </div> <div> </div> <div> Data from 4,657 patients who completed a drug questionnaire was used to inform the research. Some 579 were current marijuana users, while 1,975 had used it in the past. </div> <div> </div> <div> Those who reported using marijuana in the past month had lower levels of fasting insulin and HOMA-IR. The link was weaker in candidates that reported using marijuana at least once, but not in the past 30 days. </div> <div> </div> <div> Professor Albert commented: "These are indeed remarkable observations that are supported, as the authors note, by basic science experiments that came to similar conclusions."</div> <div> </div> <div> Previous studies have shown that while marijuana users tend to take in more calories, they often have lower body mass indexes and smaller waist circumferences. </div>
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...